(Press-News.org) ROCKVILLE, Md.— After 12 initial weeks of weight loss with intensive lifestyle intervention alone, participants in the SURMOUNT-3 study who were randomly assigned to tirzepatide for 72 weeks achieved a total mean reduction in baseline body weight of 24.3% at week 84. Results of the study, conducted by Eli Lilly & Company, will be presented during the 41st Annual Meeting of The Obesity Society (TOS) at ObesityWeek® 2023 scheduled for Oct. 14–17, in Dallas, Texas. The study will be published in the journal Nature Medicine and publication will coincide with the presentation at the conference.
"These are extraordinary findings, which show that participants -- who had already lost 6.9% of their baseline body weight with traditional diet and activity counseling -- lost an additional 18.4% of body weight when administered tirzepatide, compared with a gain of 2.5% in participants assigned to placebo,” said TOS Past President Thomas Wadden, PhD, FTOS, professor of psychology in psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Wadden is the lead author of the paper. “The additional weight loss produced further improvements, compared with placebo, in multiple measures of health, including waist circumference, blood pressure, cholesterol and triglycerides, blood sugar and physical functioning."
Ariana Chao, PhD, MSN, RN, FNP-BC, faculty associate, Johns Hopkins University School of Nursing, Baltimore, Md, and second author of the paper, will present the study and discuss its efficacy findings at ObesityWeek®.
“From the start of the intensive lifestyle intervention, participants treated with tirzepatide had an average body weight loss of 64 pounds. Health care providers have long sought strategies to help patients with obesity achieve losses of this magnitude, which can provide benefits to patients’ health and quality of life,” said Chao.
Wadden added “patients who received lifestyle intervention and tirzepatide achieved a mean weight loss consistent with that produced by sleeve gastrectomy, a widely used procedure in metabolic and bariatric surgery. Tirzepatide could offer a safe and highly effective alternative to surgery for some persons with severe obesity."
SURMOUNT-3 was a multi-center, randomized, double-blind, parallel, placebo-controlled trial that compared the efficacy and safety of tirzepatide to placebo for 72 weeks, after a 12-week intensive lifestyle intervention lead-in period in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes.
Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist, combined in a single molecule. The drug activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Tirzepatide has been shown to decrease food intake by increasing satiety and decreasing hunger and reward-based eating.
Multiple presentations of the findings will discuss: the study’s background and rationale; the study design and participants’ baseline characteristics; and the efficacy, safety and clinical results. Presentations will take place in person from 3:30 p.m. to 4:45 p.m. (CDT) on Sunday, Oct. 15, 2023 in Ballroom C at the Kay Bailey Hutchison Convention Center in Dallas, Texas.
Media representatives interested in covering the presentations need to register for ObesityWeek® 2023. Registration is free but a code is needed. Media representatives can request a code by sending an email to TOS Director of Communications and Media Relations Chanel Carrington at ccarrington@obesity.org.
For more information, visit www.obesityweek.org and research the Interactive Schedule under the Program tab.
# # #
The Obesity Society (TOS) is the leading organization of scientists and health professionals devoted to understanding and reversing the epidemic of obesity and its adverse health, economic and societal effects. Combining the perspective of researchers, clinicians, policymakers and patients, TOS promotes innovative research, education and evidence-based clinical care to improve the health and well-being of all people with obesity. For more information, visit www.obesity.org.
END
SAN FRANCISCO — Blood management programs that reduced or avoided transfusions saved a health system millions of dollars annually, with a return on investment of more than $7 for every dollar spent, while achieving the same or better outcomes, suggests research presented at the ANESTHESIOLOGY® 2023 annual meeting.
Over the past 10 years, the Johns Hopkins Health System established a comprehensive blood management program with two primary goals: 1) to reduce unnecessary transfusions across the five-hospital health system, and 2) to ...
SAN FRANCISCO — Two simple solutions could help prevent severe bleeding (postpartum hemorrhage) after cesarean delivery, suggests research presented at the ANESTHESIOLOGY® 2023 annual meeting. As the leading cause of maternal mortality in the U.S. at the time of birth, postpartum hemorrhage is more common after cesarean deliveries than vaginal births.
Both solutions help address uterine atony, which causes up to 80% of postpartum hemorrhage. Uterine atony is when, after delivery, the uterus remains soft and weak instead of contracting to compress the blood vessels that had been attached to the placenta. One solution involves infusing a medication to help the ...
SAN FRANCISCO — An automated pain recognition system using artificial intelligence (AI) holds promise as an unbiased method to detect pain in patients before, during and after surgery, according to research presented at the ANESTHESIOLOGY® 2023 annual meeting.
Currently, subjective methods are used to assess pain, including the Visual Analog Scale (VAS) — where patients rate their own pain — and the Critical-Care Pain Observation Tool (CPOT) — where health care professionals rate the patient’s pain based on facial expression, ...
SAN FRANCISCO — Patients who had common procedures performed outside of the operating room (OR) were more likely to go home instead of to a long-term care facility when they were discharged from the hospital if their sedation was administered or directed by an anesthesiologist, rather than by a physician who is not a trained anesthesiologist, according to a first-of-its-kind study presented at the ANESTHESIOLOGY® 2023 annual meeting.
Patients who need catheters placed in a vein, angiograms (X-ray of the blood vessels), image-guided biopsies and many other procedures typically are treated in the interventional radiology (IR) suite instead of the OR and given ...
About The Study: Among 2,511 adults hospitalized with acute infection, treatment with the antibiotic piperacillin-tazobactam did not increase the incidence of acute kidney injury or death in this randomized clinical trial. Treatment with the antibiotic cefepime resulted in more neurological dysfunction.
Authors: Edward T. Qian, M.D., M.Sc., of Vanderbilt University Medical Center in Nashville, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.20583)
Editor’s Note: Please see the article for additional information, including other ...
SAN FRANCISCO — Virtual reality (VR) may be an effective and reliable tool to alleviate the anxiety experienced by most parents or caregivers when their child undergoes surgery, according to research presented at the ANESTHESIOLOGY® 2023 annual meeting.
“When a child has a medical procedure, it is often emotionally unsettling for not just the patient, but the entire family,” said Thomas J. Caruso, M.D., Ph.D., FASA, senior author of the study and clinical professor of anesthesiology, perioperative and pain medicine at Stanford University, California. “By ...
SAN FRANCISCO — The American Society of Anesthesiologists (ASA) today presented Stanley W. Stead, M.D., MBA, FASA, with its 2022 Distinguished Service Award in recognition of his enduring contributions to advancing patient-centered, physician-led health care, and his advocacy related to health care economics, including value-based care and equitable physician payment models. The award is the highest honor ASA bestows and is presented annually to a member who has transformed the specialty of anesthesiology.
A nationally recognized thought leader in health care economics, information technology and quality of care, Dr. Stead ...
Tokyo, Japan – Researchers from Tokyo Metropolitan University have engineered a range of new single-walled transition metal dichalcogenide (TMD) nanotubes with different compositions, chirality, and diameters by templating off boron-nitride nanotubes. They also realized ultra-thin nanotubes grown inside the template, and successfully tailored compositions to create a family of new nanotubes. The ability to synthesize a diverse range of structures offers unique insights into their growth mechanism ...
FINDINGS
In a recent study led by Ravi Salgia, M.D., Ph.D., the Arthur & Rosalie Kaplan Chair in Medical Oncology, a team of researchers from City of Hope, one of the largest cancer research and treatment organizations in the United States, and other institutions found that nongenetic mechanisms are important in lung cancer patients who develop a resistance to one cancer therapy. Their findings were published in the October 13 issue of the journal Science Advances.
The team’s study explored resistance to the anti-cancer medication sotorasib in patients with non-small cell lung cancer (NSCLC). Sotorasib inhibits a specific mutation ...
London, Ont.,: Worldwide, millions of stroke survivors undergo prolonged cardiac monitoring, leading to the discovery of atrial fibrillation, or irregular heartbeats, in up to 1.5 million of these patients each year.
A new study, published in The Lancet Neurology, describes the knowledge on atrial fibrillation detected in patients who had a recent stroke. The publication suggests that atrial fibrillation detected post-stroke is not quite the same as the irregular heartbeats already known before a stroke.
The study, led by Western University professor Dr. Luciano Sposato, proposes that atrial fibrillation detected post-stroke exhibits distinct ...
